Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Michael A. Boxer Sells 3,775 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Thermo Fisher Scientific Trading Down 2.4 %

TMO opened at $514.40 on Wednesday. The stock’s fifty day moving average is $549.14 and its two-hundred day moving average is $560.79. The company has a market capitalization of $194.06 billion, a P/E ratio of 31.12, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TMO. Howard Capital Management Group LLC boosted its position in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after purchasing an additional 286 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after purchasing an additional 225,568 shares in the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth $1,091,000. XML Financial LLC boosted its position in shares of Thermo Fisher Scientific by 26.8% in the 3rd quarter. XML Financial LLC now owns 577 shares of the medical research company’s stock worth $357,000 after purchasing an additional 122 shares in the last quarter. Finally, Tyler Stone Wealth Management lifted its position in Thermo Fisher Scientific by 267.3% during the 3rd quarter. Tyler Stone Wealth Management now owns 371 shares of the medical research company’s stock worth $229,000 after acquiring an additional 270 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMO. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research report on Friday, January 31st. Wells Fargo & Company increased their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Morgan Stanley increased their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.